BioInvent International AB

BioInvent International AB has made a strategic move in the biotechnology sector by selling the future royalty and milestone rights for its antibody mezagitamab to XOMA Royalty Corporation for up to $30 million.

BioInvent International AB’s share price has surged to 31.15 SEK, reflecting a significant increase in market confidence in the company’s potential and strategic direction.